Skip to main content

Silence Says Lung Injury Drug Shows Promise in Animal Study

Premium

Silence Therapeutics this week announced that it has generated preclinical data showing that its acute lung injury drug Atu111 could boost the survival of mice infected with pneumonia when combined with antibiotics.

Atu111 is comprised of siRNAs against angiopoietin-2, an “antagonistic ligand of Tie-2 signaling ... implicated in progressing endothelial dysfunction in the context of disease pathogenesis for acute lung injury or sepsis,” according to Silence. It is delivered with the firm's proprietary DACC delivery technology, which specifically targets the endothelium.

The preclinical study examined Atu111 with antibiotics in Streptococcus pneumoniae-infected mice, and demonstrated a 90 percent survival benefit for treated animals compared with non-treated ones. Antibiotic treatment alone resulted in a 20 percent survival benefit compared with untreated controls, Silence said.

Silence said it has now begun collaborating with researchers at Hannover Medical School in Germany to further explore the therapeutic effects of Atu111 in animal models of acute lung injury and sepsis.

Earlier this year, Silence CEO Tony Sedgwick told Gene Silencing News that Atu111 is being prepared to enter clinical testing in 2013 (GSN 2/16/2012).

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.